Search our Site

Download the PDF here
. Download the point of care tool to assist identifying patients most likely to benefit from referral to lipid specialist or the more comprehensive review, the GECKO Messenger containing more on diagnosis, screening and management and more. Access an education module with case-based learning here.

Bottom line: Familial hypercholesterolemia is a common (~1/250) autosomal dominant disorder that results in a 6 to 22-fold increase in premature cardiovascular disease (CVD) and death. Early diagnosis and treatment can normalize life expectancy. Key features of familial hypercholesterolemia are elevated LDL-C ≥ 5mmol/L with additional features such as early onset CVD (<55 years in men, <65 years in women), cholesterol deposition in the tendons (xanthomata) and/or around the eyes (xanthelasma), arcus cornealis with onset <45years, and family history of early onset CVD or hyperlipidemia requiring treatment. In Canada, a diagnosis of familial hypercholesterolemia is typically based on an individual’s clinical presentation correlating with one of three familial hypercholesterolemia definitions. Genetic testing is not generally available, and a clinical diagnosis guides treatment and screening of family members. Once a person is diagnosed with familial hypercholesterolemia, cascade screening of family members using measurement of LDL-C levels is recommended. This enables early identification and treatment of at-risk individuals, with statins as first-line treatment.

Updated Sept 2019

What is familial hypercholesterolemia?

Familial hypercholesterolemia (FH) is an autosomal dominant genetic condition where the uptake of low-density lipoprotein cholesterol (LDL-C) into cells is either decreased or inhibited. This results in lifetime exposure to very high levels of LDL-C. FH is the most common genetic disorder causing premature cardiovascular disease (CVD) and death in both men and women.

About 1 in 250 Canadians is thought to have the heterozygous (HeFH) form of FH. FH is more common in certain populations due to founder effects: in certain areas of Quebec, the prevalence is as high as 1 in 80; it affects approximately ~1/100 Lebanese and Afrikaners, and 1/67 South African Ashkenazi Jews. FH is under diagnosed and under treated both in Canada and worldwide, despite the knowledge that early diagnosis and treatment can normalize life expectancy.

Table 1. Clinical features of familial hypercholesterolemia in heterozygotes (HeFH) and homozygotes (HoFH).

How is familial hypercholesterolemia diagnosed?

The Canadian Cardiovascular Society (CCS) recommends the use of the Canadian diagnostic criteria for FH proposed by the Familial Hypercholesterolemia Canada (FHCanada) network (Figure 1). While these criteria are relatively new, they are less complicated than those published by the Dutch Lipid Clinic Network (DLCNC) or the Simon Broome Registry (see the GEC-KO Messenger for more on these criteria) and have been validated against each of these criteria, which are internationally accepted for the diagnosis of HeFH.

Genetic testing is not necessary for diagnosis, and is not routinely available in most of Canada. In Quebec, health care providers can order testing from CHU Sainte Justine Molecular Laboratory focused on the most common gene mutations found in French Canadians with familial hypercholesterolemia

Figure 1: Canadian criteria for the clinical diagnosis of familial hypercholesterolemia (FH). From Ruel I et al., 2018 Can J Cardiol. Reprinted with permission under the CC BY-NC-ND license

ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. * Secondary causes of high LDL-C should be ruled out (severe or untreated hypothyroidism, nephrotic syndrome, hepatic disease [biliary cirrhosis], medication, especially antiretroviral agents).

Cascade screening

The most cost-effective approach for identification of new familial hypercholesterolemia cases is cascade screening of family members of the first individual with a confirmed diagnosis, known as the index case.

This approach is recommended by the Canadian Cardiovascular Society (CCS). Screening can include lipid profiles of relatives and/or genetic testing for a known familial mutation when available. Each newly diagnosed individual becomes a new index case and cascade screening of relatives continues.

Surveillance and management

Statins are the drug class of choice for individuals with HeFH. LDL-C should be lowered as fast and as far as possible. The CCS recommends a >50% reduction of LDL-C from baseline beginning at age 18 as primary prevention with a goal of LDL-C <2.0mmol/L for secondary prevention. Some individuals with FH will require combination and/or emerging therapy to obtain optimal LDL-C. Families with FH should be counselled about the importance of lifestyle modification such as smoking cessation and avoidance of passive smoking, diet, exercise, daily activity beginning early in life, maintenance of ideal body weight, and stress reduction.

Children: Lifestyle modifications discussed above remain the cornerstone of CVD prevention in both children and teens with FH and referral to a specialist for treatment decisions is recommended.

See for the comprehensive GEC-KO Messenger with complete reference list and more on HoFH. For the updated Canadian definition of FH visit to find Ruel et al., Simplified Canadian definition for familial hypercholesterolemia. Can J Cardiol 2018 34: 1210-1214.

Authors: S Morrison MS CGC, JE Allanson MD FRCPC, RA Hegele MD FRCPC, S Hadjiyannakis MD FRCPC and JC Carroll MD CCFP


·           GECKO is an independent not-for-profit program that does not accept support from commercial or non-academic entities.

·           GECKO aims to aid the practicing non-genetics clinician by providing informed resources regarding genetic/genomic conditions, services and technologies that have been developed in a rigorous and evidence-based manner with periodic updating. The content on the GECKO site is for educational purposes only. No resource should be used as a substitute for clinical judgement. GECKO assumes no responsibility or liability resulting from the use of information contained herein.

·           All clinicians using this site are encouraged to consult local genetics clinics, medical geneticists, or specialists for clarification of questions that arise relating to specific patient problems.

·           All patients should seek the advice of their own physician or other qualified clinician regarding any medical questions or conditions.

·           External links are selected and reviewed at the time a page is published. However, GECKO is not responsible for the content of external websites. The inclusion of a link to an external website from GECKO should not be understood to be an endorsement of that website or the site’s owners (or their products/services).

·           We strive to provide accurate, timely, unbiased, and up-to-date information on this site, and make every attempt to ensure the integrity of the site. However, it is possible that the information contained here may contain inaccuracies or errors for which neither GECKO nor its funding agencies assume responsibility.

Highlight: What are others reading about on GECKO

A Guide to understanding prenatal screening

A Guide to understanding prenatal screening

A resource developed for pregnant persons and their providers. Everything you wanted to know about screening from deciding whether or not have it, to results…

Read more

Latest News

The GEC-KO team will be presenting at the 2021 University of Ottawa’s Annual Refresher Course

Have some questions about how Canada’s genetic non-discrimination act works and what it means for your practice?

Check out this 2022 article in Canadian Family Physician

Read more